SCHEMBL17838980

SCHEMBL17838980

CC(NC(=O)CCCCCl)c1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.63
ALDH1A1 P00352 6/20 0.63
HPGD P15428 2/20 0.63
GAA P10253 2/20 0.63
KMT2A Q03164 3/20 0.58
L3MBTL1 Q9Y468 1/20 0.57
MEN1 O00255 2/20 0.55
POLB P06746 1/20 0.55
GPR139 Q6DWJ6 2/20 0.52
ASAH1 Q13510 1/20 0.52
ACER2 Q5QJU3 1/20 0.52
HTT P42858 1/20 0.52
NPC1 O15118 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17838978 1.00 MAPT (0.63) MAPTALDH1A1HPGDGAAKMT2A
SCHEMBL6400133 0.89 MAPT (0.69) MAPTALDH1A1HPGDGAAKMT2A
SCHEMBL6398811 0.89 MAPT (0.69) MAPTALDH1A1HPGDGAAKMT2A
SCHEMBL31373866 0.89 MAPT (0.69) MAPTALDH1A1HPGDGAAKMT2A
SCHEMBL1153625 0.85 HTT (0.60) MAPTALDH1A1HPGDGAAKMT2A
SCHEMBL4139305 0.84 ALDH1A1 (0.72) MAPTALDH1A1HPGDGAAKMT2A
SCHEMBL9472620 0.84 ALDH1A1 (0.72) MAPTALDH1A1HPGDGAAKMT2A
SCHEMBL5599045 0.84 ALDH1A1 (0.72) MAPTALDH1A1HPGDGAAKMT2A
SCHEMBL4183115 0.84 ALDH1A1 (0.72) MAPTALDH1A1HPGDGAAKMT2A
SCHEMBL4139311 0.84 ALDH1A1 (0.72) MAPTALDH1A1HPGDGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3237401-A1 ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR Pfizer Inc (US) 2017-11-01 EP disclosed
US-9738626-B2 Antagonists of prostaglandin EP3 receptor PFIZER INC. (US) 2017-08-22 US disclosed
WO-2016103097-A1 ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR PFIZER INC. (US) 2016-06-30 WO disclosed
US-20160176851-A1 ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR PFIZER INC. (US) 2016-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160176851-A1 ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR PTGER3, PTGES3, PTGER2 MAPT 4882/4885ALDH1A1 2682/4885HPGD 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.